ASHM has been notified that Bristol-Myers Squibb (BMS) Australia has decided to remove BaracludeTM from the Pharmaceutical Benefits Scheme (PBS) from 1 July 2021.

They note that the use of BaracludeTM has decreased significantly over time, with generic versions of the medicine now accounting for 64% of the market.

To minimise the impact of this decision on patients they are giving early notice to health authorities and by working with the HCP community to ensure time to consider transitioning patients to one of 9 generic versions of BaracludeTM on the PBS or other appropriate treatment option.  The generic versions can be found here:

Please reach out to the HBV team at if you have any questions or concerns about next steps.